Expanding the eligibility for transcatheter aortic valve implantation the trans-subclavian retrograde approach using: the III generation CoreValve revalving system
Our aim was to assess the safety and feasibility of the retrograde trans-subclavian approach to transcatheter aortic valve implantation (TAVI) in selected high-risk patients with aortic stenosis (AS) and severe peripheral vasculopathy. TAVI is an emerging therapeutic option to treat inoperable/high-...
Saved in:
Published in | JACC. Cardiovascular interventions Vol. 2; no. 9; pp. 828 - 833 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.09.2009
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Our aim was to assess the safety and feasibility of the retrograde trans-subclavian approach to transcatheter aortic valve implantation (TAVI) in selected high-risk patients with aortic stenosis (AS) and severe peripheral vasculopathy.
TAVI is an emerging therapeutic option to treat inoperable/high-risk patients affected by symptomatic AS. However, these patients are also often affected by severe iliac-femoral arteriopathy, rendering the transfemoral approach unemployable for percutaneous revalving procedure.
From among those patients in our department between May 2007 and December 2008, who were refused surgical aortic valve replacement because of high surgical risk and were ineligible for transfemoral percutaneous aortic valve replacement, we scheduled 3 for TAVI by the subclavian approach. Procedures were performed by a combined team of cardiologists, cardiac surgeons, and anesthetists in the catheterization laboratory. The III generation CoreValve Revalving System (CoreValve Inc., Irvine, California) with an 18-F delivery system was introduced in all cases by the left subclavian artery.
Prosthetic valves were successfully implanted in all 3 cases, leading to a fall in transvalvular gradient without significant paravalvular regurgitation. No intraprocedural or periprocedural complications occurred. Two patients developed an atrioventricular block requiring the implantation of a permanent pacemaker. All patients were discharged in asymptomatic status, with good prosthesis performance. No adverse events occurred within the 3-month follow-up.
TAVI by subclavian retrograde approach seems safe and feasible in inoperable/high-risk patients with AS and peripheral vasculopathy, who are neither eligible for surgical valve replacement nor transfemoral percutaneous aortic valve implantation. Further studies are needed to evaluate the long-term efficacy of this new therapy. |
---|---|
AbstractList | OBJECTIVESOur aim was to assess the safety and feasibility of the retrograde trans-subclavian approach to transcatheter aortic valve implantation (TAVI) in selected high-risk patients with aortic stenosis (AS) and severe peripheral vasculopathy.BACKGROUNDTAVI is an emerging therapeutic option to treat inoperable/high-risk patients affected by symptomatic AS. However, these patients are also often affected by severe iliac-femoral arteriopathy, rendering the transfemoral approach unemployable for percutaneous revalving procedure.METHODSFrom among those patients in our department between May 2007 and December 2008, who were refused surgical aortic valve replacement because of high surgical risk and were ineligible for transfemoral percutaneous aortic valve replacement, we scheduled 3 for TAVI by the subclavian approach. Procedures were performed by a combined team of cardiologists, cardiac surgeons, and anesthetists in the catheterization laboratory. The III generation CoreValve Revalving System (CoreValve Inc., Irvine, California) with an 18-F delivery system was introduced in all cases by the left subclavian artery.RESULTSProsthetic valves were successfully implanted in all 3 cases, leading to a fall in transvalvular gradient without significant paravalvular regurgitation. No intraprocedural or periprocedural complications occurred. Two patients developed an atrioventricular block requiring the implantation of a permanent pacemaker. All patients were discharged in asymptomatic status, with good prosthesis performance. No adverse events occurred within the 3-month follow-up.CONCLUSIONSTAVI by subclavian retrograde approach seems safe and feasible in inoperable/high-risk patients with AS and peripheral vasculopathy, who are neither eligible for surgical valve replacement nor transfemoral percutaneous aortic valve implantation. Further studies are needed to evaluate the long-term efficacy of this new therapy. Our aim was to assess the safety and feasibility of the retrograde trans-subclavian approach to transcatheter aortic valve implantation (TAVI) in selected high-risk patients with aortic stenosis (AS) and severe peripheral vasculopathy. TAVI is an emerging therapeutic option to treat inoperable/high-risk patients affected by symptomatic AS. However, these patients are also often affected by severe iliac-femoral arteriopathy, rendering the transfemoral approach unemployable for percutaneous revalving procedure. From among those patients in our department between May 2007 and December 2008, who were refused surgical aortic valve replacement because of high surgical risk and were ineligible for transfemoral percutaneous aortic valve replacement, we scheduled 3 for TAVI by the subclavian approach. Procedures were performed by a combined team of cardiologists, cardiac surgeons, and anesthetists in the catheterization laboratory. The III generation CoreValve Revalving System (CoreValve Inc., Irvine, California) with an 18-F delivery system was introduced in all cases by the left subclavian artery. Prosthetic valves were successfully implanted in all 3 cases, leading to a fall in transvalvular gradient without significant paravalvular regurgitation. No intraprocedural or periprocedural complications occurred. Two patients developed an atrioventricular block requiring the implantation of a permanent pacemaker. All patients were discharged in asymptomatic status, with good prosthesis performance. No adverse events occurred within the 3-month follow-up. TAVI by subclavian retrograde approach seems safe and feasible in inoperable/high-risk patients with AS and peripheral vasculopathy, who are neither eligible for surgical valve replacement nor transfemoral percutaneous aortic valve implantation. Further studies are needed to evaluate the long-term efficacy of this new therapy. |
Author | Napodano, Massimo Gasparetto, Valeria Bonato, Raffaele Pittarello, Demetrio Isabella, Giambattista Bianco, Roberto Fraccaro, Chiara Gerosa, Gino Ramondo, Angelo Iliceto, Sabino Tarantini, Giuseppe |
Author_xml | – sequence: 1 givenname: Chiara surname: Fraccaro fullname: Fraccaro, Chiara email: chiara_fraccaro@hotmail.com organization: Department of Interventional Cardiology, University of Padova, Padova, Italy. chiara_fraccaro@hotmail.com – sequence: 2 givenname: Massimo surname: Napodano fullname: Napodano, Massimo – sequence: 3 givenname: Giuseppe surname: Tarantini fullname: Tarantini, Giuseppe – sequence: 4 givenname: Valeria surname: Gasparetto fullname: Gasparetto, Valeria – sequence: 5 givenname: Gino surname: Gerosa fullname: Gerosa, Gino – sequence: 6 givenname: Roberto surname: Bianco fullname: Bianco, Roberto – sequence: 7 givenname: Raffaele surname: Bonato fullname: Bonato, Raffaele – sequence: 8 givenname: Demetrio surname: Pittarello fullname: Pittarello, Demetrio – sequence: 9 givenname: Giambattista surname: Isabella fullname: Isabella, Giambattista – sequence: 10 givenname: Sabino surname: Iliceto fullname: Iliceto, Sabino – sequence: 11 givenname: Angelo surname: Ramondo fullname: Ramondo, Angelo |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19778770$$D View this record in MEDLINE/PubMed |
BookMark | eNo1kE1PwzAMhiMEYh_wBzig3Di1pJ9puKFpwKRJXIBr5SXulqlNS5JO7PfwR-k-ONmyH7-v7Qm5NK1BQu4iFkYsyh-34VZqE8aMiZDl4VC6IOOo4HnAc5aNyMS5LWM5Ezy-JqNIcF5wzsbkd_7TgVHarKnfIMVar_VK19rvadVa6i0YJ2FoebQUWuu1pDuod0h109VgPHjdmuPskQ1cv5I17DQYatHbdm1BIYWusy3IDe3dYPV05BeLBV2jQXuSmLUWv47KFg8Oh5Xc3nlsbshVBbXD23Ocks-X-cfsLVi-vy5mz8tgE6fCB0owiLNUYQU8XxWAUREjlyoWoEBKEYlUxAyQJVXGBCZQ5WkmhBryKEUVJ1PycNIddv3u0fmy0U5iPZyJbe9KnqQsKzKWDeT9mexXDaqys7oBuy___5r8AShxgLc |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.jcin.2009.06.016 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1876-7605 |
EndPage | 833 |
ExternalDocumentID | 19778770 |
Genre | Research Support, Non-U.S. Gov't Journal Article Case Reports |
GroupedDBID | --- --K --M .1- .FO .~1 0R~ 0SF 18M 1B1 1P~ 1~. 4.4 457 4G. 53G 5GY 5VS 6I. 7-5 8P~ AACTN AAEDT AAEDW AAFTH AAIKJ AALRI AAOAW AAQFI AAXUO ABBQC ABFRF ABJNI ABMAC ABMZM ABVKL ABXDB ACGFO ACGFS ADBBV ADEZE ADMUD ADVLN AEFWE AEKER AEVXI AEXQZ AFCTW AFETI AFJKZ AFRHN AFTJW AGHFR AGYEJ AITUG AJOXV AJRQY ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ BAWUL BLXMC CGR CS3 CUY CVF DIK EBS ECM EIF EJD F5P FDB FEDTE FNPLU GBLVA H13 HVGLF HZ~ IXB J1W M41 MO0 N9A NCXOZ NPM O-L O9- OAUVE OA~ OK1 OL0 P-8 P-9 P2P PC. Q38 RIG ROL SDF SEL SES SSZ T5K W8F Z5R 7X8 |
ID | FETCH-LOGICAL-h249t-d90a254defa76b8ae182e7cd29adacc9194920ae03f509e3af64599d09e14ed23 |
IngestDate | Fri Aug 16 22:42:54 EDT 2024 Sat Sep 28 07:48:53 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-h249t-d90a254defa76b8ae182e7cd29adacc9194920ae03f509e3af64599d09e14ed23 |
Notes | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
PMID | 19778770 |
PQID | 734058505 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_734058505 pubmed_primary_19778770 |
PublicationCentury | 2000 |
PublicationDate | 2009-Sep 20090901 |
PublicationDateYYYYMMDD | 2009-09-01 |
PublicationDate_xml | – month: 09 year: 2009 text: 2009-Sep |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | JACC. Cardiovascular interventions |
PublicationTitleAlternate | JACC Cardiovasc Interv |
PublicationYear | 2009 |
SSID | ssj0060972 |
Score | 2.3221548 |
Snippet | Our aim was to assess the safety and feasibility of the retrograde trans-subclavian approach to transcatheter aortic valve implantation (TAVI) in selected... OBJECTIVESOur aim was to assess the safety and feasibility of the retrograde trans-subclavian approach to transcatheter aortic valve implantation (TAVI) in... |
SourceID | proquest pubmed |
SourceType | Aggregation Database Index Database |
StartPage | 828 |
SubjectTerms | Aged Aged, 80 and over Aortic Valve Stenosis - complications Aortic Valve Stenosis - diagnostic imaging Aortic Valve Stenosis - surgery Aortography - methods Cardiac Catheterization - adverse effects Cardiac Catheterization - instrumentation Feasibility Studies Heart Valve Prosthesis Heart Valve Prosthesis Implantation - adverse effects Heart Valve Prosthesis Implantation - instrumentation Humans Logistic Models Male Patient Selection Peripheral Vascular Diseases - complications Peripheral Vascular Diseases - diagnostic imaging Prosthesis Design Risk Assessment Severity of Illness Index Subclavian Artery - diagnostic imaging Time Factors Tomography, X-Ray Computed Treatment Outcome |
Title | Expanding the eligibility for transcatheter aortic valve implantation the trans-subclavian retrograde approach using: the III generation CoreValve revalving system |
URI | https://www.ncbi.nlm.nih.gov/pubmed/19778770 https://search.proquest.com/docview/734058505 |
Volume | 2 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3JbtswEIYJNwWKXoJ0TbqBh94EGTK1MrfAdRK3sXuxC98ESqRaB4EkyFJQ5HX6FHm7DhdLcpqiy0UQBJGWPZ9IDv3PDELvCQEfwHVTeMU5AweFOzaNuJBFBDIaJr7ZGpjNg_Ol93HlrwaD255qqamTYXpzb1zJ_1gVroFdZZTsP1i27RQuwDnYF45gYTj-lY0n30sTlaKkGVJcrLSuWoRZy2lIpWWViRBZIdtb8PHXQsZGXrHcCA1lW3WvvWmS9Ipdy3e-ErVSbnHRph23pEb-61YIMp1OZfllYQgaF5X4ovquZAJxvU2hskTvLH9PxuOhFJnsaGB7ssteNApLZUkhLQlYs6qdPuasLDhTFcOtGSz9AbZu-wG-Rr1WVaqss3WzEWXZgnvGNlJtX6u6URY8q1FYd5senaoL5iw9UMMoboeB4_dHctIDlvZG5cjEn5sJXmfe-GXu0NsYl8PLdJ2bRKbB0Bndk6h7_jk-XV5cxIvJavEAPSQh9aWa9MP003YREMisSCZGS8sJ7_b6e49GrWwWB2jfuCT4RPP1BA1E_hQ9mhnRxTP0o8UMg-FxDzMMmOEdzLDGDCvMcB8z1fYuZrjDDG8xwwqzY3U_QIY7yHALGW4hwxqy52h5OlmMz21T28P-Bg5_bXPqMOJ7XGQsDJKICfBzRZhyQhkHvuiIepQ4TDhuBuOFcFkmsx5RDucjT3DivkB7eZGLQ4S5E1BGqR_RMPU8NwVjJBlNYO2cEZhyyBHC2186hrFT_iHGclE0mzh0wV2JwAc4Qi-1BeJS53iJR-AXRWHovPpz49focYfoG7RXV414CyvVOnmnmPgJxNmjZA |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Expanding+the+eligibility+for+transcatheter+aortic+valve+implantation+the+trans-subclavian+retrograde+approach+using%3A+the+III+generation+CoreValve+revalving+system&rft.jtitle=JACC.+Cardiovascular+interventions&rft.au=Fraccaro%2C+Chiara&rft.au=Napodano%2C+Massimo&rft.au=Tarantini%2C+Giuseppe&rft.au=Gasparetto%2C+Valeria&rft.date=2009-09-01&rft.eissn=1876-7605&rft.volume=2&rft.issue=9&rft.spage=828&rft.epage=833&rft_id=info:doi/10.1016%2Fj.jcin.2009.06.016&rft.externalDBID=NO_FULL_TEXT |